What do systematic reviews say?

Intervention not reported

• Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 431 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pembrolizumab vs chemotherapy alone

Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).

• Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
  MD 9.05 [4.61, 13.5]
  1 study · 519 participants
  Low

Intervention not reported

The intervention showed no clear difference in quality of life (better indicated by higher values) (high certainty).

• The role of iron in the management of chemotherapy‐induced anemia in cancer patients receiving… 2016 · Cochrane Headline outcomes only
  SMD 0.01
  3 studies · 1124 participants
  High

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hysterectomy (simple or radical) with chemoradiotherapy vs internal radiotherapy (brachytherapy) with chemoradiotherapy

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2054 participants
  Very low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.88 [0.74, 1.04]
  2 studies · 1154 participants
  Low

Intervention not reported

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1801 participants
  Low

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

The review found no eligible studies for this question.

• Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
  None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
  0 studies
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Immune checkpoint inhibitors vs any first‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 393 participants
  Moderate

Immune checkpoint inhibitors vs any second‐line chemotherapy

• Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 727 participants
  Low

Summary of Findings Table ‐ Enoxaparin vs no enoxaparin

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

The review found no eligible studies for this question.

• Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

The review found no eligible studies for this question.

• PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found